Special Issue

The Role Precision Medicine in the Field of Cancer Oncology

Message from the Guest Editor

Topics of Interest Include, but are not limited to:

- Genomic profiling and targeted therapies
- Artificial Intelligence and machine learning in diagnostic pathology
- Data analytics for treatment optimization
- individualized treatment plans
- Role of immunotherapy in precision medicine
- Real-world applications of precision medicine in oncology
- The development of precision medicine for pediatric oncology

We invite original research articles and reviews from researchers and clinicians to contribute to this multidisciplinary special issue. The aim is to create a comprehensive and insightful collection of articles that shed light on how precision medicine is revolutionizing cancer treatment, from bench to bedside.

Guest Editor

Dr. Tze-Kiong Er

Division of Laboratory Medicine, Asia University Hospital, Taichung, Taiwan Department of Medical Laboratory Science and Biotechnology, Asia University, Taichung, Taiwan

Deadline for manuscript submissions

closed (30 November 2024)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/192456

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).